Produktname:2-Aminonicotinaldehyde

IUPAC Name:2-aminopyridine-3-carbaldehyde

CAS:7521-41-7
Molekulare Formel:C6H6N2O
Reinheit:98%
Katalognummer:CM103325
Molekulargewicht:122.13

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM103325-25g in stock ʼnNJ
CM103325-100g in stock ƓƓŹ
CM103325-500g in stock ůŹưĽ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:7521-41-7
Molekulare Formel:C6H6N2O
Schmelzpunkt:-
SMILES-Code:O=CC1=C(N)N=CC=C1
Dichte:
Katalognummer:CM103325
Molekulargewicht:122.13
Siedepunkt:
Mdl-Nr.:MFCD01830382
Lagerung:Keep in dark place, inert atmosphere, store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Bexotegrast
Pliant announced positive safety and exploratory efficacy data from the INTEGRIS-PSC Phase 2a trial of Bexotegrast (PLN-74809) 320 mg in patients with primary sclerosing cholangitis and suspected liver ibrosis. PLN-74809 is an oral small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins for the treatment of IPF and PSC. While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients and the bile ducts of PSC patients where they activate TGF-β, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF-β activation, potentially halting the growth of scar tissue.